Literature DB >> 20179984

Indispensability of UGT1A1*6 genotyping in Japanese cancer patients treated with irinotecan.

Masashi Takano, Masafumi Kato, Tomoyuki Yoshikawa, Tomoko Goto, Kenichi Furuya, Yoshihiro Kikuchi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20179984     DOI： 10.1007/s10147-010-0024-2

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN： 1341-9625            Impact factor:   3.402


× No keyword cloud information.
  4 in total

1.  Re: UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.

Authors:  Wataru Ichikawa; Kazuhiro Araki; Ken-ichi Fujita; Wataru Yamamoto; Hisashi Endo; Fumio Nagashima; Ryuhei Tanaka; Toshimichi Miya; Keiji Kodama; Yu Sunakawa; Masaru Narabayashi; Yuichi Ando; Yuko Akiyama; Kaori Kawara; Yasutsuna Sasaki
Journal:  J Natl Cancer Inst       Date:  2008-01-29       Impact factor: 13.506

2.  Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study.

Authors:  Masashi Takano; Masafumi Kato; Tomoyuki Yoshikawa; Naoki Sasaki; Junko Hirata; Kenichi Furuya; Michiko Takahashi; Harushige Yokota; Nao Kino; Koji Horie; Tomoko Goto; Keiichi Fujiwara; Kenji Ishii; Yoshihiro Kikuchi; Tsunekazu Kita
Journal:  Oncology       Date:  2009-03-20       Impact factor: 2.935

3.  UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients.

Authors:  Masahide Onoue; Tomohiro Terada; Masahiko Kobayashi; Toshiya Katsura; Shigemi Matsumoto; Kazuhiro Yanagihara; Takafumi Nishimura; Masashi Kanai; Satoshi Teramukai; Akira Shimizu; Masanori Fukushima; Ken-ichi Inui
Journal:  Int J Clin Oncol       Date:  2009-04-24       Impact factor: 3.402

4.  UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.

Authors:  Janelle M Hoskins; Richard M Goldberg; Pingping Qu; Joseph G Ibrahim; Howard L McLeod
Journal:  J Natl Cancer Inst       Date:  2007-08-28       Impact factor: 13.506
  4 in total
  1 in total

1.  Geographic difference in advanced gastric cancer prevalence and chemotherapy treatment results: could it really be an independent prognostic factor?

Authors:  Junichi Sakamoto; Koji Oba
Journal:  Gastric Cancer       Date:  2012-07       Impact factor: 7.370
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.